Skip to main content
SYBX
OTC Life Sciences

A 28.3% shareholder bloc locks in support for the Synlogic–Caldera merger, removing a key obstacle to closing.

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.12
Mkt Cap
$13.1M
52W Low
$0.54
52W High
$1.96
52W Position info
107% above low
Off High info
43% below high
Rel. Volume info
45× avg
Market data snapshot near publication time

SYBX has more than doubled off its 52-week low of $0.54 on elevated volume (45× avg).

Summary

A 28.3% shareholder group has agreed to support Synlogic's merger with Caldera Therapeutics, providing a critical vote bloc and reducing deal uncertainty.


Key Events · M&A and Partnerships · SYBX

  • 28.3% Holder Enters Support Agreement

    Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver, owning 3,312,219 shares (28.3% of Synlogic), signed a support agreement to vote for the Caldera merger and against competing proposals.

  • Irrevocable Proxy Granted

    The group granted an irrevocable proxy to Synlogic to vote their shares on the merger, preventing any last-minute change of heart.

  • Transfer Restrictions Imposed

    The support agreement restricts the group from selling or transferring their shares, ensuring their stake remains committed through the vote.

  • Merger Agreement Announced Same Day

    The support agreement was executed concurrently with the definitive merger agreement between Synlogic and Caldera Therapeutics, disclosed in an 8-K earlier today.


Analysis · SYBX · Life Sciences

A support agreement signed by Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver — together controlling 28.3% of Synlogic — commits their votes to the Caldera Therapeutics merger. By locking in this substantial bloc, the risk of a shareholder rebellion drops sharply and the path to closing becomes far more certain. The pact also restricts share sales and grants an irrevocable proxy, underscoring a major investor's strong commitment.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SYBX was trading at $1.12 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.1M. The 52-week trading range was $0.54 to $1.96. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SYBX - Latest Insights

SYBX
Nov 10, 2026, 7:02 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.9602 info
Change: -$0.0698 (-7%) info
Market Cap: $11.761M info
SYBX
Nov 05, 2026, 8:54 AM EST
Filing Type: 425
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.9602 info
Change: -$0.0398 (-4%) info
Market Cap: $11.761M info
SYBX
Aug 11, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.18
Real-time Price: $0.9602 info
Change: -$0.2198 (-19%) info
Market Cap: $11.761M info
SYBX
Jul 29, 2026, 7:40 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $1.12
Real-time Price: $0.9602 info
Change: -$0.1598 (-14%) info
Market Cap: $11.761M info
SYBX
Jul 29, 2026, 7:19 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.720
Real-time Price: $0.9602 info
Change: +$0.2402 (+33%) info
Market Cap: $11.761M info